Osmotic delivery of therapeutic compounds by solubility enhancement
US7611728B2 · kind B2 · utility
69Cited by
37References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 5, 2003 |
| Grant date | Nov 3, 2009 |
| Priority date | — |
| Expiry date | Sep 14, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P3/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to the oral osmotic delivery of therapeutic compounds that have limited solubility in an aqueous environment due to inherent hydrophobicity or to saturation limitations in the core of the osmotic system. The present invention is suitable for the osmotic delivery of glipizide and other hydrophobic drugs, but runs the spectrum to other therapeutic agents with higher aqueous solubilities, yet having a solubility limitation in an osmotic dosage unit due to high drug load.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.